Efficacy of Kelofan syrup on COVID-19

Evaluating efficacy of Kelofan syrup, a traditional Iranian medicine product, on pulmonary and other clinical and laboratory manifestations of patients with probable or confirmed COVID-19

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200405046960N1

Enrollment

Registered

2020-04-08

Start date

2020-04-09

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: COVID-19. Condition 2: COVID-19. COVID19, virus identified COVID19, virus not identified

Interventions

In the intervention group, in addition to the standard treatment, medicinal herbal products will be prescribed. The drug will be given in syrup form. The syrup will contain the following medicinal her

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 18 years old Hospitalized patients with probable or confirmed COVID-19 based on radiological findings or positive PCR test according to the instructions of the Ministry of Health Clinically classified as moderate and severe, no need for intubation Written and informed satisfaction of patients

Exclusion criteria

Exclusion criteria: Liver, kidney and heart failure History of allergies to medicinal herbs Immunodeficiency Hypertension Diabetes Alcohol or drug addiction Patients with transplanted organs Cor Pulmonel Patients Taking anticoagulants, antiarrhythmics, antihypertensives, corticosteroids and immunosuppressants Pregnancy Breast feeding

Design outcomes

Primary

Measure	Time frame
Oxygen saturation. Timepoint: Clinical examination and Pulse Oximetry before starting medication and regularly during treatment. Method of measurement: Pulse Oximeter.;Respiratory Rate. Timepoint: Clinical examination before starting medication and regularly during treatment. Method of measurement: Respiratory Count.	—

Secondary

Measure	Time frame
Liver enzymes. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.;C-reactive protein. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.;Lymphocytes. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.;White Cell blood count. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.	—

Measure

Time frame

Liver enzymes. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.;C-reactive protein. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.;Lymphocytes. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.;White Cell blood count. Timepoint: Intravenous blood testing before starting medication and during treatment. Method of measurement: Venous blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Nasimi Doost Azgomi

Ardabil University of Medical Sciences

modir7060@yahoo.com+98 45 3142 2529

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026